Literature DB >> 20031381

Metabolic toxicity of the heart: insights from molecular imaging.

P Iozzo1.   

Abstract

There is convincing evidence that alterations in myocardial substrate use play an important role in the normal and diseased heart. In this review, insights gained by using quantitative molecular imaging by positron emission tomography and magnetic resonance spectroscopy in the study of human myocardial metabolism will be discussed, and attention will be paid to the effects of nutrition, gender, aging, obesity, diabetes, cardiac hypertrophy, ischemia, and heart failure. The heart is an omnivore organ, relying on metabolic flexibility, which is compromised by the occurrence of defects in coronary flow reserve, insulin-mediated glucose disposal, and metabolic-mechanical coupling. Obesity, diabetes, and ischemic cardiomyopathy appear as states of high uptake and oxidation of fatty acids, that compromise the ability to utilize glucose under stimulated conditions, and lead to misuse of energy and oxygen, disturbing mechanical efficiency. Idiopathic heart failure is a complex disease frequently coexisting with diabetes, insulin resistance and hypertension, in which the end stage of metabolic toxicity manifests as severe mitochondrial disturbance, inability to utilize fatty acids, and ATP depletion. The current literature provides evidence that the primary events in the metabolic cascade outlined may originate in extra-cardiac organs, since fatty acid, glucose levels, and insulin action are mostly controlled by adipose tissue, skeletal muscle and liver, and that a broader vision of organ cross-talk may further our understanding of the primary and the adaptive events involved in metabolic heart toxicity. (c) 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20031381     DOI: 10.1016/j.numecd.2009.08.011

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  15 in total

1.  Aging, metabolic syndrome and the heart.

Authors:  Guarner Veronica; Rubio-Ruiz Maria Esther
Journal:  Aging Dis       Date:  2012-03-13       Impact factor: 6.745

2.  DNA methylation reprograms cardiac metabolic gene expression in end-stage human heart failure.

Authors:  Mark E Pepin; Stavros Drakos; Chae-Myeong Ha; Martin Tristani-Firouzi; Craig H Selzman; James C Fang; Adam R Wende; Omar Wever-Pinzon
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-07-12       Impact factor: 4.733

3.  Prolonged QT interval and lipid alterations beyond β-oxidation in very long-chain acyl-CoA dehydrogenase null mouse hearts.

Authors:  Roselle Gélinas; Julie Thompson-Legault; Bertrand Bouchard; Caroline Daneault; Asmaa Mansour; Marc-Antoine Gillis; Guy Charron; Victor Gavino; François Labarthe; Christine Des Rosiers
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-06-17       Impact factor: 4.733

Review 4.  Glucose metabolism and cardiac hypertrophy.

Authors:  Stephen C Kolwicz; Rong Tian
Journal:  Cardiovasc Res       Date:  2011-05-01       Impact factor: 10.787

Review 5.  The role of epicardial and perivascular adipose tissue in the pathophysiology of cardiovascular disease.

Authors:  D Margriet Ouwens; Henrike Sell; Sabrina Greulich; Juergen Eckel
Journal:  J Cell Mol Med       Date:  2010-09       Impact factor: 5.310

6.  Cardiac energy dependence on glucose increases metabolites related to glutathione and activates metabolic genes controlled by mechanistic target of rapamycin.

Authors:  Jonathan C Schisler; Trisha J Grevengoed; Florencia Pascual; Daniel E Cooper; Jessica M Ellis; David S Paul; Monte S Willis; Cam Patterson; Wei Jia; Rosalind A Coleman
Journal:  J Am Heart Assoc       Date:  2015-02-24       Impact factor: 5.501

7.  Trimetazidine therapy for diabetic mouse hearts subjected to ex vivo acute heart failure.

Authors:  Emilene Breedt; Lydia Lacerda; M Faadiel Essop
Journal:  PLoS One       Date:  2017-06-20       Impact factor: 3.240

8.  Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine.

Authors:  Weena J Y Chen; Michaela Diamant; Karin de Boer; Hendrik J Harms; Lourens F H J Robbers; Albert C van Rossum; Mark H H Kramer; Adriaan A Lammertsma; Paul Knaapen
Journal:  Cardiovasc Diabetol       Date:  2017-05-19       Impact factor: 9.951

9.  Cardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and in vitro studies.

Authors:  Sabrina Greulich; Weena J Y Chen; Bujar Maxhera; Luuk J Rijzewijk; Rutger W van der Meer; Jacqueline T Jonker; Heidi Mueller; Daniella Herzfeld de Wiza; Ralf-Ruediger Floerke; Konstantinos Smiris; Hildo J Lamb; Albert de Roos; Jeroen J Bax; Johannes A Romijn; Jan W A Smit; Payam Akhyari; Artur Lichtenberg; Juergen Eckel; Michaela Diamant; D Margriet Ouwens
Journal:  PLoS One       Date:  2013-03-29       Impact factor: 3.240

10.  Clinical importance of epicardial adipose tissue.

Authors:  Eszter Nagy; Adam L Jermendy; Bela Merkely; Pal Maurovich-Horvat
Journal:  Arch Med Sci       Date:  2016-10-26       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.